• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to the Letter to the Editor regarding "The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland" by Yang and colleagues.

作者信息

Everts-Graber Judith, Reichenbach Stephan, Lehmann Thomas

机构信息

OsteoRheuma Bern AG, Bahnhofplatz 1, CH-3011, Bern, Switzerland.

Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

出版信息

Osteoporos Int. 2025 Feb;36(2):343-344. doi: 10.1007/s00198-024-07282-3. Epub 2024 Oct 28.

DOI:10.1007/s00198-024-07282-3
PMID:39466420
Abstract
摘要

相似文献

1
Response to the Letter to the Editor regarding "The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland" by Yang and colleagues.对Yang及其同事发表的《关于“罗莫单抗对骨密度的影响取决于既往治疗：瑞士一项前瞻性、多中心队列研究”致编辑的信》的回复。
Osteoporos Int. 2025 Feb;36(2):343-344. doi: 10.1007/s00198-024-07282-3. Epub 2024 Oct 28.
2
The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.罗莫佐单抗对既往治疗的骨密度影响：瑞士前瞻性、多中心队列研究。
Osteoporos Int. 2024 Sep;35(9):1605-1613. doi: 10.1007/s00198-024-07155-9. Epub 2024 Jun 26.
3
Letter to the Editor Regarding "The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland".致编辑的信：关于“罗莫佐单抗对骨密度的影响取决于既往治疗情况：瑞士一项前瞻性多中心队列研究 ”
Osteoporos Int. 2025 Feb;36(2):341-342. doi: 10.1007/s00198-024-07281-4. Epub 2024 Oct 28.
4
Verifying the effectiveness of romosozumab re-administration on bone mineral density.验证罗莫佐单抗再次给药对骨密度的有效性。
J Bone Miner Res. 2025 Feb 2;40(2):201-210. doi: 10.1093/jbmr/zjae196.
5
Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.骨质疏松症患者 denosumab 和 romosozumab 对骨密度和骨转换标志物影响的荟萃分析。
Front Endocrinol (Lausanne). 2023 Jul 12;14:1188969. doi: 10.3389/fendo.2023.1188969. eCollection 2023.
6
Romosozumab in postmenopausal women with low bone mineral density.罗莫佐单抗治疗绝经后低骨密度妇女。
N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
7
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.罗莫单抗治疗低骨密度的疗效和安全性：一项系统评价和荟萃分析。
Clin Rheumatol. 2020 Nov;39(11):3261-3276. doi: 10.1007/s10067-020-04948-1. Epub 2020 May 8.
8
Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women.在绝经后女性中，地诺单抗治疗后使用罗莫单抗比继续使用地诺单抗更能提高腰椎骨密度和小梁骨评分。
J Bone Miner Res. 2025 Feb 2;40(2):184-192. doi: 10.1093/jbmr/zjae179.
9
The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment.与先前治疗相比，罗莫佐单抗治疗后转换疗法在骨质疏松症治疗中的效果。
J Osteoporos. 2024 Jan 9;2024:2144527. doi: 10.1155/2024/2144527. eCollection 2024.
10
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.罗莫单抗对低骨量绝经前女性骨密度和小梁骨评分的影响。
Osteoporos Int. 2025 Feb;36(2):323-331. doi: 10.1007/s00198-024-07336-6. Epub 2025 Jan 15.

本文引用的文献

1
The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.罗莫佐单抗对既往治疗的骨密度影响：瑞士前瞻性、多中心队列研究。
Osteoporos Int. 2024 Sep;35(9):1605-1613. doi: 10.1007/s00198-024-07155-9. Epub 2024 Jun 26.
2
Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).真实世界证据：骨质疏松症研究的新机遇。来自欧洲临床和经济骨关节炎、骨质疏松症和肌肉骨骼疾病学会（ESCEO）的工作组的建议。
Osteoporos Int. 2023 Aug;34(8):1283-1299. doi: 10.1007/s00198-023-06827-2. Epub 2023 Jun 23.
3
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.唑来膦酸对罗莫单抗/地诺单抗治疗后骨质流失的影响：2年随访
Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.